Abstract:γ9δ2T cells, which express Vγ9 and Vδ2 chains of the T cell receptor (TCR), mediate cancer immune surveillance by sensing early metabolic changes in malignant leukemic blast and not their healthy hematopoietic stem counterparts via the γ9δ2TCR targeting joined conformational and spatial changes of CD277 at the cell membrane (CD277J). This concept led to the development of next generation CAR-T cells, so-called TEGs: αβT cells Engineered to express a defined γδTCR. The high affinity γ9δ2TCR clone 5 has recently been selected within the TEG format as a clinical candidate (TEG001). However, exploring safety and efficacy against a target, which reflects an early metabolic change in tumor cells, remains challenging given the lack of appropriate tools. Therefore, we tested whether TEG001 is able to eliminate established leukemia in a primary disease model, without harming other parts of the healthy hematopoiesis in vivo.Separate sets of NSG mice were respectively injected with primary human acute myeloid leukemia (AML) blasts and cord blood-derived human progenitor cells from healthy donors. These mice were then treated with TEG001 and mock cells. Tumor burden and human cells engraftment were measured in peripheral blood and followed up over time by quantifying for absolute cell number by flow cytometry. Statistical analysis was performed using non-parametric 2-tailed Mann-Whitney t-test.We successfully engrafted primary AML blasts and healthy hematopoietic cells after 6–8 weeks. Here we report that metabolic cancer targeting through TEG001 eradicated established primary leukemic blasts in vivo, while healthy hematopoietic compartments derived from human cord-blood remained unharmed in spite of TEGs persistence up to 50 days after infusion. No additional signs of off-target toxicity were observed in any other tissues.Within the limitations of humanized PD-X models, targeting CD277J by TEG001 is safe and efficient. Therefore, we have initiated clinical testing of TEG001 in a phase I first-in-human clinical trial (NTR6541; date of registration 25 July 2017).

Determination of human γδ T cell-mediated cytotoxicity using a non-radioactive assay system

Anti-γδ TCR Antibody-Expanded Γδ T Cells: a Better Choice for the Adoptive Immunotherapy of Lymphoid Malignancies

Expansion and Immunological Study of Human Tumor Infiltrating Gamma/Delta T Lymphocytes in vitro<sup>1</sup>

Identification of Human T Cell Receptor Γδ-Recognized Epitopes/Proteins Via CDR3δ Peptide-based Immunobiochemical Strategy

Effect of γδT Cells in Tumor

Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application

Exploring γδ T cells for use in non-MHC restricted immunotherapy

Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays

Investigation of NK cell function against two target hematological cell line using radioactive chromium assay

Cytotoxicity of Human Hepatic Intrasinusoidal Gamma/Delta T Cells Depends on Phospho-antigen and NK Receptor Signaling

Study on the effect of γδ T cells expanded in vitro to kill hepatocellular carcinoma cells

An optimized cultivation method for future in vivo application of γδ T cells

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay

Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse

A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells

Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells

Suppression of Graft-Versus-host Disease and Amplification of Graft-Versus-tumor Effects by Activated Natural Killer Cells after Allogeneic Bone Marrow Transplantation.

919 Exploring New Strategies for Improved ADCC Responses with Humanized NK Cells

Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control

Antibody-targeted T cells and natural killer cells for cancer immunotherapy

Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells